Association between Artificial Light at Night Exposure and breast and prostate cancer risk – the review
Keywordscircadian rhythm, artificial light, breast cancer, prostate cancer
Introduction and purpose: Light is one of the defining features of life on the Earth, allowing certain biological processes to be subordinated to its presence and absence. With the introduction of artificial light, the human natural biological clock was dysregulated. Apart from that, the studies showed a connection between exposure to artificial light at night (ALAN) and carcinogenesis. The aim of this review was to present currently available knowledge in the online database PubMed about Association Between Artificial Light at Night and Breast and Prostate Cancer Risk
Brief description of the state of knowledge: The article covers clinical and population-based control studies which indicate to ALAN exposure can lead to increased incidence of breast and prostate cancer by disruption of circadian rhythms in several mechanisms involving suppression of melatonin production, dysregulation of sleep–activity pattern and disruption of circadian genes.
Conclusions: The review support an assumption that breast and prostate cancer incidence is a consequence of ALAN exposure. Further studies should clarify the relationship between ALAN exposure and other types of cancer. Besides, ALAN exposure levels should be measured more precisely than by satellite pictures analysis to reliably conduct studies proving the relation between ALAN exposure and risk of cancer development.
B.-P. D et al., “Circadian rhythms from multiple oscillators: lessons from diverse organisms,” Nat. Rev. Genet., vol. 6, no. 7, pp. 544–556, Jul. 2005, doi: 10.1038/NRG1633.
H. F, W. C, P. EK, and T. K, “Light pollution as a biodiversity threat,” Trends Ecol. Evol., vol. 25, no. 12, pp. 681–682, Dec. 2010, doi: 10.1016/J.TREE.2010.09.007.
G. KJ, V. ME, and H. F, “The biological impacts of artificial light at night: the research challenge,” Philos. Trans. R. Soc. Lond. B. Biol. Sci., vol. 370, no. 1667, May 2015, doi: 10.1098/RSTB.2014.0133.
F. Falchi et al., “The new world atlas of artificial night sky brightness,” Sci. Adv., vol. 2, no. 6, p. e1600377, Jun. 2016, doi: 10.1126/SCIADV.1600377.
C. CA et al., “Stability, precision, and near-24-hour period of the human circadian pacemaker,” Science, vol. 284, no. 5423, pp. 2177–2181, Jun. 1999, doi: 10.1126/SCIENCE.284.5423.2177.
R. MR, F. RG, D. FC, and M. M, “Transplanted suprachiasmatic nucleus determines circadian period,” Science, vol. 247, no. 4945, pp. 975–978, 1990, doi: 10.1126/SCIENCE.2305266.
T. K, A. J, and S. DJ, “An action spectrum for melatonin suppression: evidence for a novel non-rod, non-cone photoreceptor system in humans,” J. Physiol., vol. 535, no. Pt 1, pp. 261–267, Aug. 2001, doi: 10.1111/J.1469-7793.2001.T01-1-00261.X.
B. GC et al., “Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor,” J. Neurosci., vol. 21, no. 16, pp. 6405–6412, Aug. 2001, doi: 10.1523/JNEUROSCI.21-16-06405.2001.
Y. J and G. A, “Robust synchronization of the cell cycle and the circadian clock through bidirectional coupling,” J. R. Soc. Interface, vol. 16, no. 158, 2019, doi: 10.1098/RSIF.2019.0376.
S. A, “Circadian Clock, Cell Division, and Cancer: From Molecules to Organism,” Int. J. Mol. Sci., vol. 18, no. 4, Apr. 2017, doi: 10.3390/IJMS18040873.
Y. WS, D. Q, F. WY, W. WY, and W. X, “Light exposure at night, sleep duration, melatonin, and breast cancer: a dose-response analysis of observational studies,” Eur. J. Cancer Prev., vol. 23, no. 4, pp. 269–276, 2014, doi: 10.1097/CEJ.0000000000000030.
H. S et al., “Light at night and breast cancer risk among California teachers,” Epidemiology, vol. 25, no. 5, pp. 697–706, 2014, doi: 10.1097/EDE.0000000000000137.
G.-S. A et al., “Evaluating the Association between Artificial Light-at-Night Exposure and Breast and Prostate Cancer Risk in Spain (MCC-Spain Study),” Environ. Health Perspect., vol. 126, no. 4, Apr. 2018, doi: 10.1289/EHP1837.
M.-S. S, M. S, L. J, C.-G. A, J.-L. JC, and M. M, “An Overview of the Polymorphisms of Circadian Genes Associated With Endocrine Cancer,” Front. Endocrinol. (Lausanne)., vol. 10, no. FEB, 2019, doi: 10.3389/FENDO.2019.00104.
Z. X, S. M, C. D, and S. A, “Casein kinase 1 promotes synchrony of the circadian clock network,” Mol. Cell. Biol., vol. 34, no. 14, pp. 2682–2694, Jul. 2014, doi: 10.1128/MCB.01571-13.
P. N et al., “The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator,” Cell, vol. 110, no. 2, pp. 251–260, Jul. 2002, doi: 10.1016/S0092-8674(02)00825-5.
C. H et al., “Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β,” Nature, vol. 485, no. 7396, pp. 123–127, May 2012, doi: 10.1038/NATURE11048.
L. D, W. LL, D. T, and W. DK, “NPAS2 Compensates for Loss of CLOCK in Peripheral Circadian Oscillators,” PLoS Genet., vol. 12, no. 2, Feb. 2016, doi: 10.1371/JOURNAL.PGEN.1005882.
S. TK et al., “A functional genomics strategy reveals Rora as a component of the mammalian circadian clock,” Neuron, vol. 43, no. 4, pp. 527–537, Aug. 2004, doi: 10.1016/J.NEURON.2004.07.018.
M. G, L. MO, V. M, C. T, and C. V, “A Timeless Link Between Circadian Patterns and Disease,” Trends Mol. Med., vol. 22, no. 1, pp. 68–81, Jan. 2016, doi: 10.1016/J.MOLMED.2015.11.007.
F. L and K. NM, “The circadian clock in cancer development and therapy,” Prog. Mol. Biol. Transl. Sci., vol. 119, pp. 221–282, 2013, doi: 10.1016/B978-0-12-396971-2.00009-9.
F. J, S. HR, B. F, F. D, M. C, and P. DM, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” Int. J. cancer, vol. 127, no. 12, pp. 2893–2917, Dec. 2010, doi: 10.1002/IJC.25516.
L. C, W. DR, and R. SM, “Direct association between mouse PERIOD and CKIepsilon is critical for a functioning circadian clock,” Mol. Cell. Biol., vol. 24, no. 2, pp. 584–594, Jan. 2004, doi: 10.1128/MCB.24.2.584-594.2004.
R. E and P. M, “Circadian Genes in Breast Cancer,” Adv. Clin. Chem., vol. 75, pp. 53–70, 2016, doi: 10.1016/BS.ACC.2016.03.005.
S. T et al., “The consensus coding sequences of human breast and colorectal cancers,” Science, vol. 314, no. 5797, pp. 268–274, Oct. 2006, doi: 10.1126/SCIENCE.1133427.
L. M et al., “Altered circadian genes expression in breast cancer tissue according to the clinical characteristics,” PLoS One, vol. 13, no. 6, Jun. 2018, doi: 10.1371/JOURNAL.PONE.0199622.
C. C et al., “Loss of circadian clock gene expression is associated with tumor progression in breast cancer,” Cell Cycle, vol. 13, no. 20, pp. 3282–3291, Oct. 2014, doi: 10.4161/15384101.2014.954454.
R. S et al., “Polymorphisms in circadian genes, night work and breast cancer: results from the GENICA study,” Chronobiol. Int., vol. 31, no. 10, pp. 1115–1122, Dec. 2014, doi: 10.3109/07420528.2014.957301.
T. T et al., “Breast cancer risk, nightwork, and circadian clock gene polymorphisms,” Endocr. Relat. Cancer, vol. 21, no. 4, pp. 629–638, 2014, doi: 10.1530/ERC-14-0121.
K. T et al., “Opposite Carcinogenic Effects of Circadian Clock Gene BMAL1,” Sci. Rep., vol. 8, no. 1, Dec. 2018, doi: 10.1038/S41598-018-34433-4.
W. J et al., “Circadian protein BMAL1 promotes breast cancer cell invasion and metastasis by up-regulating matrix metalloproteinase9 expression,” Cancer Cell Int., vol. 19, no. 1, Jul. 2019, doi: 10.1186/S12935-019-0902-2.
F. L and L. CC, “The circadian clock: pacemaker and tumour suppressor,” Nat. Rev. Cancer, vol. 3, no. 5, pp. 350–361, May 2003, doi: 10.1038/NRC1072.
M. S, T. S, B. C, and R. CR, “Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies,” BMC Med., vol. 16, no. 1, Feb. 2018, doi: 10.1186/S12916-018-1010-1.
Z. Y et al., “Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study,” Cancer Res., vol. 69, no. 24, pp. 9315–9322, Dec. 2009, doi: 10.1158/0008-5472.CAN-09-0648.
C. Q et al., “A role for the clock gene per1 in prostate cancer,” Cancer Res., vol. 69, no. 19, pp. 7619–7625, Oct. 2009, doi: 10.1158/0008-5472.CAN-08-4199.
K. Z and G. PM, “WOMEN IN CANCER THEMATIC REVIEW: Circadian rhythmicity and the influence of ‘clock’ genes on prostate cancer,” Endocr. Relat. Cancer, vol. 23, no. 11, pp. T123–T134, Nov. 2016, doi: 10.1530/ERC-16-0366.
C. LW et al., “Variants in circadian genes and prostate cancer risk: a population-based study in China,” Prostate Cancer Prostatic Dis., vol. 11, no. 4, pp. 342–348, 2008, doi: 10.1038/SJ.PCAN.4501024.
L. DW et al., “Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality,” Cancer Epidemiol. Biomarkers Prev., vol. 20, no. 9, pp. 1928–1936, Sep. 2011, doi: 10.1158/1055-9965.EPI-11-0236.
M. SC et al., “Circadian clock genes and risk of fatal prostate cancer,” Cancer Causes Control, vol. 26, no. 1, pp. 25–33, Jan. 2015, doi: 10.1007/S10552-014-0478-Z.
A. O. AA et al., “A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer,” Nat. Genet., vol. 46, no. 10, pp. 1103–1109, Sep. 2014, doi: 10.1038/NG.3094.
K. CCM et al., “Artificially lit surface of Earth at night increasing in radiance and extent,” Sci. Adv., vol. 3, no. 11, Nov. 2017, doi: 10.1126/SCIADV.1701528.
F. F, C. P, E. CD, K. DM, and H. A, “Limiting the impact of light pollution on human health, environment and stellar visibility,” J. Environ. Manage., vol. 92, no. 10, pp. 2714–2722, Oct. 2011, doi: 10.1016/J.JENVMAN.2011.06.029.
W. H. Walker et al., “Light Pollution and Cancer,” Int. J. Mol. Sci., vol. 21, no. 24, pp. 1–18, Dec. 2020, doi: 10.3390/IJMS21249360.
C. AM, A. D, D. JF, and C. CA, “Evening use of light-emitting eReaders negatively affects sleep, circadian timing, and next-morning alertness,” Proc. Natl. Acad. Sci. U. S. A., vol. 112, no. 4, pp. 1232–1237, Jan. 2015, doi: 10.1073/PNAS.1418490112.
T. T, H. M, A. A, V. AI, and H. T, “Incidence of breast cancer in Norwegian female radio and telegraph operators,” Cancer Causes Control, vol. 7, no. 2, pp. 197–204, 1996, doi: 10.1007/BF00051295.
H. J, “Increased breast cancer risk among women who work predominantly at night,” Epidemiology, vol. 12, no. 1, pp. 74–77, 2001, doi: 10.1097/00001648-200101000-00013.
D. S, M. DK, and S. RG, “Night shift work, light at night, and risk of breast cancer,” J. Natl. Cancer Inst., vol. 93, no. 20, pp. 1557–1562, Oct. 2001, doi: 10.1093/JNCI/93.20.1557.
K. Papantoniou et al., “Breast cancer risk and night shift work in a case–control study in a Spanish population,” Eur. J. Epidemiol. 2015 319, vol. 31, no. 9, pp. 867–878, Jul. 2015, doi: 10.1007/S10654-015-0073-Y.
I. Kloog, A. Haim, and B. A. Portnov, “Using kernel density function as an urban analysis tool: Investigating the association between nightlight exposure and the incidence of breast cancer in Haifa, Israel,” Comput. Environ. Urban Syst., vol. 33, no. 1, pp. 55–63, Jan. 2009, doi:
K. I, H. A, S. RG, B. M, and P. BA, “Light at night co-distributes with incident breast but not lung cancer in the female population of Israel,” Chronobiol. Int., vol. 25, no. 1, pp. 65–81, Jan. 2008, doi: 10.1080/07420520801921572.
S. E. Bauer, S. E. Wagner, J. Burch, R. Bayakly, and J. E. Vena, “A case-referent study: light at night and breast cancer risk in Georgia,” Int. J. Health Geogr., vol. 12, p. 23, Apr. 2013, doi: 10.1186/1476-072X-12-23.
K. I, S. RG, H. A, and P. BA, “Nighttime light level co-distributes with breast cancer incidence worldwide,” Cancer Causes Control, vol. 21, no. 12, pp. 2059–2068, Dec. 2010, doi: 10.1007/S10552-010-9624-4.
R. N, H. A, and P. BA, “Artificial Light at Night (ALAN) and breast cancer incidence worldwide: A revisit of earlier findings with analysis of current trends,” Chronobiol. Int., vol. 32, no. 6, pp. 757–773, Jul. 2015, doi: 10.3109/07420528.2015.1043369.
L. KY, S. C, N. MY, C. LWT, G. J, and W. C, “Exposure to light at night (LAN) and risk of breast cancer: A systematic review and meta-analysis,” Sci. Total Environ., vol. 762, Mar. 2021, doi: 10.1016/J.SCITOTENV.2020.143159.
K. I, H. A, S. RG, and P. BA, “Global co-distribution of light at night (LAN) and cancers of prostate, colon, and lung in men,” Chronobiol. Int., vol. 26, no. 1, pp. 108–125, Jan. 2009, doi: 10.1080/07420520802694020.
K. Papantoniou et al., “Night shift work, chronotype and prostate cancer risk in the MCC-Spain case-control study,” Int. J. Cancer, vol. 137, no. 5, pp. 1147–1157, Sep. 2015, doi: 10.1002/IJC.29400.
How to Cite
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 365
Number of citations: 0